News

Update of the Annotated Model Grant Agreement

Published on | 2 days ago

Programmes HorizonEU L+F

The Commission has added several clarifications on the Annotated Model Grant Agreement (AMGA) (update 1 April 2025).

The additions are listed on page 4/5 and in the document highlighted by a green square on the left hand side.

Some clarifications out of this list:

  • several details of the personnel cost calculations
  • link to a guidance document concerning Funding Support to Third Parties (p. 166- but seemingly not available yet)
  • link to a guidance document about System and Process Audit (SPA) (p. 257)
  • about Gender Equality Plan in Annex 5 (p. 356)
  • link to a guidance document regarding restricted calls (calls with ownership and control restrictions) (Annex 5, p. 396, but seemingly not available yet) in Annex 5

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1553 articles available search in articles 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.